Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
002821.SZ
STRONG BUYFLAGAsymchem Laboratories (Tianjin) Co., Ltd. · Healthcare · China · $6.3B · Avg Vol: $115M/d
Asymchem is a leading CDMO with strong technical capabilities. While it fits the CDMO pricing power theme, it faces severe geopolitical headwinds from Western legislative efforts (such as the US Biosecure Act) targeting Chinese biotech partners.
COMPANY DESCRIPTION
Asymchem Laboratories (Tianjin) Co., Ltd. is a leading global contract development and manufacturing organization (CDMO) providing customized services for the pharmaceutical industry. The company specializes in small molecule drug development and commercial manufacturing, utilizing advanced continuous flow chemistry and green manufacturing technologies. It maintains a strong competitive position through long-term partnerships with global multinational pharmaceutical companies and high-quality regulatory compliance.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 1.5B | 1.2B | 858M | 986M | -13.4% |
| EPS | 1.33 | 0.93 | 0.40 | 0.47 | -29.5% |
| Shares | 370M | 370M | 368M | 361M | -2.5% |
| Debt | 20M | 22M | 48M | 46M | 30.7% |
| Equity | 2.3B | 2.6B | 2.5B | 2.6B | 4.1% |
| Op CF | 486M | 525M | 185M | 208M | -24.6% |
| Inv CF | -690M | -398M | -175M | -94M | — |
| Fin CF | -110M | -80M | -285M | -51M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002821.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 002821.SZ | Asymchem Laboratories (Tianjin) Co., Ltd.(you) | $6.3B | 83 | STRONG BUY |
| 688336.SS | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd | $5.9B | 82 | STRONG BUY |
| 688578.SS | Shanghai Allist Pharmaceuticals Co., Ltd. | $6.0B | 94 | STRONG BUY |
| 1530.HK | 3SBio Inc. | $5.9B | 96 | STRONG BUY |
| 002007.SZ | Hualan Biological Engineering Inc. | $3.7B | 78 | BUY |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $17.6B | 87 | STRONG BUY |
| 300009.SZ | Anhui Anke Biotechnology (Group) Co., Ltd. | $2.1B | 85 | STRONG BUY |
| 3759.HK | Pharmaron Beijing Co., Ltd. | $4.1B | 60 | HOLD |
| 002653.SZ | Haisco Pharmaceutical Group Co., Ltd. | $8.5B | 56 | HOLD |
| 688278.SS | Xiamen Amoytop Biotech Co., Ltd. | $3.4B | 57 | HOLD |
Peer medians: ROE 4.7% · P/E 27.8x · Gross margin 53.2%